tacrolimus

(redirected from Advagraf)
Also found in: Medical.

ta·cro·li·mus

(tə-krō′lə-məs)

An immunosuppressive drug produced by the actinomycete Streptomyces tsukubaensis, C₄₄H₆₉NO₁₂, used in combination with corticosteroids to prevent rejection of organ transplants.

[t(sukubaensis), specific epithet (after Mount Tsukuba, Japan, near which the actinomycete was discovered) + (m)acrol(ide) im(m)u(no)s(uppressant).]

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

Translations

tacrolimus

n tacrolimus m, tacrolimús m (INN)

Mentioned in ?

sirolimus

References in periodicals archive ?

Immunosuppressive therapy before and after RALP N = 12 Before RALP After RALP A: Calcineurin inhibitors 11/12 * (91.7%) 7/12 (58.3%) (Prograf, Advagraf) B: Corticosteroids 5/12 (41.7%) 4/12 (33.3%) C: Antimetabolite 10/12 (83.3%) 6/12 (50%) (Cellcept) D: mTor inhibitors 0/12 (0%) 8/12 * (66.7%) (Rapamune, Certican) RALP: robot-assisted laparoscopic radical prostatectomy; mTOR: mammalian target of rapamycin.

Technical feasibility of robot-assisted laparoscopic radical prostatectomy in renal transplant recipients: results of a series of 12 consecutive cases

In US tests, Advagraf boosted survival of transplanted livers by 8% compared with patients treated with twice-daily Tacrolimus which costs PS1.23 a time.

9000 RUSH TO SAVE DONOR-PLEA TWINS; Mirror readers sign up for Luis & Kian

Although sales in the Americas were down 6%, sales in Europe were up 24%, and the once-daily formulation Advagraf, was up 35%, while Asia and Oceania and Japan sales were up 32% and 2%, respectively.

20 Astellas

Astellas was granted marketing approval for tacrolimus extended release capsules under the trade name Advagraf in Europe in 2007 and under the trade name Graceptor in Japan in 2008.

FDA accepts Astellas' NDA for tacrolimus extended release caps in adult kidney, male liver recipients

Astellas markets tacrolimus extended release capsules under the trade name Advagraf in Europe, and as Graceptor in Japan.

Astellas Pharma US, Inc submits New Drug Application for tacrolimus extended release capsules

Advagraf is a once-daily modified release formulation of Astellas' Prograf(R) (tacrolimus, twice-daily formulation) for prevention of transplant rejection in kidney or liver recipients.